William Shell

From Wikipedia, the free encyclopedia
Jump to: navigation, search

William Elson Shell, M.D., (September 8, 1942-March 28, 2017)[1]) is an American cardiologist and inventor of weight-loss products. He owns several U.S. patents.[2] Shell has been banned from the securities industry for life as a result of a federal SEC conviction (see below).


Shell is a graduate of the University of Michigan Medical School. Following medical school he did an internship and residency at University Hospital in Ann Arbor, Michigan. He then completed a three-year fellowship in cardiovascular medicine under Eugene Braunwald at the University of California, San Diego. He then served two years as the Chief of the Coronary Care Unit at Keesler Air Force Base. Shell has been certified in cardiovascular disease and internal medicine by the American Board of Internal Medicine since 1974. He was the founder, former Chairman of the Board, CEO and Chief Scientific Officer at Targeted Medical Pharma, Inc. in Los Angeles, California, a specialty pharmaceutical company that develops and distributes medical food products.

He led the team that discovered the cardio specific enzyme CK-MB.

From 1982 to 1995, Shell was a member of the cardiology staff at Cedars of Lebanon Hospital and Mount Sinai Hospital. During his tenure, he planned, directed and implemented the merger of the coronary care unit at Cedars of Lebanon and Mount Sinai Hospital to what is now known as Cedars-Sinai Medical Center in Los Angeles, California. In addition he directed the Cardiac Cath Lab and Cardiac Rehabilitation Center at Cedar-Sinai Medical Center. Dr. Shell was also Director of the Cardiac Catheterization Laboratory and Director of Cardiac Rehabilitation. He was a member of the research team at the Myocardial Infarction Research Unit, a $5 million per year research grant from the National Institute of Health. Under that program he was a national leader in the definitions and recognition of silent heart disease. He also published seminal papers of the implication of prostaglandins in heart disease. In addition, he participated in the planning, funding and administration of NIH grants and managed a biochemistry research laboratory at Cedars-Sinai Medical Center. Ultimately, he left Cedars-Sinai Medical Center in a patent dispute to enter private practice in Beverly Hills. He was a founder in Beverly Glen Medical Systems that developed techniques for transtelephonic monitoring of cardiac rhythm disturbances and autonomic nervous system function using 24-hour electrocardiographic recordings for which he published the first American paper on prolapsed mitral valve syndrome. In 1967, he was the first American physician on the American Soviet Exchange Program for which he received a presidential citation from President Richard Nixon, one of the only presidential citations given to an American physician. He has published numerous peer reviewed articles in significant medical journals. He has been granted 27 American patents on various aspects of cardiovascular disease and has more than 12 new patent applications pending at the U.S. Patent Office.

He recently[when?] published new data regarding the nutritional management of pain using the amino acid based medical food Theramine in the American Journal of Therapeutics,[3] in addition to new data regarding the nutritional management of sleep disorders [4] and the nutritional management of PTSD.[5]

Commercial activity[edit]

As an entrepreneur, Shell developed multiple patents for Targeted Medical Pharma governing the processes involved in amino acid based medical food products. Dr. Shell the former CEO of Physician Therapeutics created the following products: Theracodophen-650 Convenience Pack (Hydrocodone 10 mg, Acetaminophen 650 mg, and Theramine); Strazepam Convenience Pack (Temazepam 15 mg and Sentra PM); Gabazolamine-0.5 Convenience Pack (Alprazolam 0.5 mg and GABAdone); Gaboxetine Convenience Pack (Fluoxetine 10 mg and GABAdone); Trazamine Convenience Pack (Tradazone 50 mg and Sentra PM); Senophylline Convenience Pack (Theophylline 100 mg and Sentra PM); Therapentin-60 (Gabapentin 200 mg and Theramine); Prazolamine (Carisoprodol 350 mg and Theramine); Sentradine (Ranitidine 150 mg and Sentra PM); and Therafeldamine (Piroxicam 20 mg and Theramine)[6] Dr. Shell successfully defended these products listed in the warning letter and subsequently worked with FDA to register these products in their database as well as the NIH Dailymed database.[7] Previous products include the Fat Magnet, a product that uses cellulose to trap fat and bind with it.[8]

Shell also formulated SeQuester, a "natural nutritional fat sequestrant", which added bile to the fibrous matter, claiming to trap fat and allow it to pass through the digestive system without being absorbed by the body.[9]

Federal conviction and lifetime ban from the securities industry[edit]

Shell was previously Chairman and Chief Executive Officer of Interactive Medical Technologies Ltd ("IMT"), a publicly traded company on the "pink sheets". Shell and Clark M. "Buzz" Holcomb were sued by the Securities and Exchange Commission for an illegal unregistered distribution of shares. Both Shell and Holcomb were convicted and permanently barred from the U.S. securities industry as a result, and Shell was additionally fined $35,000. Shell and Holcomb were prosecuted by SEC Enforcement Division prosecutors Alan Rubinstein and Jason Sabot, assisted by SEC Enforcement Division investigator Stanley Skubina. The enforcement action was agreed and signed on August 13, 1997. IMT signed a consent decree in June 1997.[10][11]


  1. ^ [1][dead link]
  2. ^ Including:US application 7674482, William E. Shell, "Method and compositions for potentiating pharmaceuticals with amino acid based medical foods", published 2010-09-10, assigned to Targeted Medical Pharma, Inc.  and US application 7585523, William E. Shell, "Composition and Method to Augment and Sustain Neurotransmitter Production", published 2004-03-04, assigned to Targeted Medical Pharma, Inc. 
  3. ^ "Search Results : American Journal of Therapeutics". journals.lww.com. 
  4. ^ MD, William E. Shell; MD, Lawrence A. May; BS, Debora H. Bullias; CRA; CRC; CRA, Stephanie L. Pavlik; MD, David S. Silver (23 April 2012). "Sentra PM (a Medical Food) and Trazodone in the Management of Sleep Disorders". Journal of Central Nervous System Disease. 2012 (4). doi:10.4137/JCNSD.S9381. PMC 3619436Freely accessible. PMID 23650468. 
  5. ^ Shell, William E.; Charuvastra, Marcus; Breitstein, Mira; Pavlik, Stephanie L.; Charuvastra, Anthony; May, Lawrence; Silver, David S. (8 October 2014). "Administration of an Amino Acid–Based Regimen for the Management of Autonomic Nervous System Dysfunction Related to Combat-Induced Illness". Journal of Central Nervous System Disease. 2014 (6). doi:10.4137/JCNSD.S13793. PMC 4197905Freely accessible. PMID 25336998. 
  6. ^ [2][dead link]
  7. ^ "DailyMed - THERACODOPHEN-650 - hydrocodone bitartrate, acetaminophen, .gamma.-aminobutyric acid". dailymed.nlm.nih.gov. 
  8. ^ NCAHF (July–August 1989). "Fat Magnet Trial". National Council Against Health Fraud Newsletter. 
  9. ^ "Living - Nonfat Pills -- The Jury Is Still Out On Sequester - Seattle Times Newspaper". community.seattletimes.nwsource.com. 
  10. ^ https://www.sec.gov/news/digest/1997/dig081497.pdf
  11. ^ https://www.sec.gov/Archives/edgar/data/1036915/0001047469-98-004954.txt

External links[edit]